On January 17, 2019 Physicians’ Education Resource (PER), a leading resource for continuing medical education (CME), reported that it will host its 15th annual International Symposium on Melanoma and Other Cutaneous Malignancies Saturday, Feb. 9, at the InterContinental New York Times Square in New York City. This educational conference will be co-chaired by Omid Hamid, M.D., chief of translational research and immunotherapy and director of melanoma therapeutics at The Angeles Clinic and Research Institute and Jeffrey S. Weber, M.D., Ph.D., deputy director of the Perlmutter Cancer Center at New York University Langone Health.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are looking forward to hosting our International Symposium on Melanoma and Other Cutaneous Malignancies once again in New York City," said Phil Talamo, president of PER. "Now in its 15th year, the symposium continues to provide physicians with the tools they need to personalize care for every patient they treat with skin and other cutaneous including some very exciting data in the adjuvant setting."
Throughout the international conference, world-renowned melanoma experts Hamid and Weber, along with distinguished skin cancer specialists, will host several sessions covering topics such as current advances in immunotherapy and targeted therapies, the benefits of regional therapy, how to use predictive and prognostic modeling and how to manage treatment-related adverse events associated with emerging strategies. This symposium will also feature a Medical Crossfire, in which the expert panel will address attendees’ questions and participate in a rigorous debate on pressing issues faced by the skin cancer treatment community.
This highly interactive symposium will also feature a special presentation, "We Are What We Eat: How the Microbiome Influences Responses to Immunotherapy in Cancer," by Thomas F. Gajewski, M.D., Ph.D., AbbVie Foundation professor of cancer immunotherapy at University of Chicago Medicine. Gajewski investigates and develops new treatments for patients with melanoma. He also serves as an editor for Cancer Research and the Journal for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper).
The 15th annual International Symposium on Melanoma and Other Cutaneous Malignancies is a one-day conference, revolutionizing the presentation of emerging therapies and evolving standards of care in the management of patients with melanoma and other skin cancers. Attendees who attend this educational conference will gain insight on the latest strategies for the use of checkpoint inhibitors, current and emerging treatments for the BRAF gene as it affects mutant melanoma, and mitigating treatment-related toxicities with targeted therapy and immunotherapies.